Allied Biotech Corporation (1780.TWO)
TWD 16.9
(0.0%)
TWD 16.9
(0.0%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Operating Cash Flow | 137.61 Million | 164.27 Million | 72.42 Million | 59.48 Million | - |
| Net Income | 122.38 Million | 185.03 Million | 17.57 Million | 101.52 Million | - |
| Depreciation & Amortization | 69.45 Million | 71.75 Million | 65.23 Million | 61.62 Million | - |
| Deferred income taxes | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - |
| Change in working capital | -12.63 Million | -89.63 Million | 3.27 Million | -83.01 Million | - |
| Other non-cash items | -2.67 Million | 6.27 Million | 9.6 Million | 3.78 Million | - |
| Investing Cash Flow | -40.93 Million | 219.01 Million | -180.93 Million | 33.84 Million | - |
| Investments in PPE | -47.9 Million | -54.65 Million | -49.98 Million | -56.82 Million | - |
| Acquisitions | - | - | - | - | - |
| Investment purchases | - | - | -130.95 Million | - | -27.07 Million |
| Sales/Maturities of investments | 6.97 Million | 273.56 Million | - | 91.11 Million | - |
| Other Investing Activities | -6000.00 | - | - | -453 Thousand | 10 Thousand |
| Financing Cash Flow | -158.32 Million | -461.99 Million | 164.23 Million | 200.66 Million | - |
| Debt repayment | -38.3 Million | -408.3 Million | -246.69 Million | -301.69 Million | - |
| Dividends payments | -114.46 Million | -47.67 Million | -76.12 Million | -94.89 Million | - |
| Common Stock Repurchased | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - |
| Other Financing Activities | 304 Thousand | 315 Thousand | 124 Thousand | - | - |
| Accounts receivables | 8.68 Million | - | - | - | - |
| Accounts payables | -10.69 Million | - | - | - | - |
| Inventory | -5 Million | -88.38 Million | -22.84 Million | -46.29 Million | - |
| Other working capital | -16.31 Million | - | - | - | - |
| Cash at beginning of period | 679.75 Million | 757.38 Million | 703.47 Million | 408.79 Million | - |
| Cash at end of period | 618.49 Million | 679.75 Million | 757.38 Million | 703.47 Million | - |
| Capital Expenditure | -47.9 Million | -54.65 Million | -49.98 Million | -56.82 Million | - |
| Effect of forex changes on cash | 393 Thousand | 1.07 Million | -1.82 Million | 698 Thousand | - |
| Net cash flow / Change in cash | -61.25 Million | -77.63 Million | 53.9 Million | 294.68 Million | - |
| Free Cash Flow | 89.7 Million | 109.61 Million | 22.44 Million | 2.65 Million | - |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 34.24 Million | 34.24 Million | 122.38 Million | 18.63 Million | 18.63 Million | 30.06 Million |
| Depreciation & Amortization | 15.42 Million | 15.42 Million | 69.45 Million | 16.75 Million | 16.75 Million | 17.97 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | 23.93 Million | 23.93 Million | -12.63 Million | 3.84 Million | 3.84 Million | -6.15 Million |
| Other non-cash items | 1.54 Million | 1.54 Million | -2.67 Million | -7.32 Million | -7.32 Million | -4.63 Million |
| Investing Cash Flow | 36.59 Million | 36.59 Million | -40.93 Million | 2.24 Million | 2.24 Million | -23.06 Million |
| Investments in PPE | -5.49 Million | -5.49 Million | -47.9 Million | -9.8 Million | -9.8 Million | -14.14 Million |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | 6.97 Million | - | - | - |
| Other Investing Activities | 42.08 Million | 42.08 Million | -6000.00 | 12.04 Million | 12.04 Million | -8.91 Million |
| Financing Cash Flow | 13.97 Million | 13.97 Million | -158.32 Million | -83.11 Million | -83.11 Million | 3.95 Million |
| Debt repayment | - | - | -38.3 Million | - | - | - |
| Dividends payments | - | - | -114.46 Million | -57.23 Million | -57.23 Million | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | 13.97 Million | 13.97 Million | 304 Thousand | -25.88 Million | -25.88 Million | 3.95 Million |
| Accounts receivables | -9.68 Million | -9.68 Million | - | 292.5 Thousand | 292.5 Thousand | 4.01 Million |
| Accounts payables | - | - | - | - | - | - |
| Inventory | 26 Million | 26 Million | -5 Million | 2.14 Million | 2.14 Million | -4.64 Million |
| Other working capital | 7.61 Million | 7.61 Million | - | 1.4 Million | 1.4 Million | -5.52 Million |
| Cash at beginning of period | - | - | 679.75 Million | - | 716.37 Million | 698.06 Million |
| Cash at end of period | 126.16 Million | 126.16 Million | 618.49 Million | -48.93 Million | 667.43 Million | 716.37 Million |
| Capital Expenditure | -5.49 Million | -5.49 Million | -47.9 Million | -9.8 Million | -9.8 Million | -14.14 Million |
| Effect of forex changes on cash | 458 Thousand | 458 Thousand | 393 Thousand | 24 Thousand | 24 Thousand | 172.5 Thousand |
| Net cash flow / Change in cash | 126.16 Million | 126.16 Million | -61.25 Million | -48.93 Million | -48.93 Million | 18.31 Million |
| Free Cash Flow | 69.64 Million | 69.64 Million | 89.7 Million | 22.1 Million | 22.1 Million | 23.09 Million |
LPX
4242
AVI
BAKK
DAWN
RNK